About INNOVENT BIO Company

Established in 2011, Cinda Biopharmaceutical Group is a leading biopharmaceutical company with the mission of developing high-quality biopharmaceuticals that ordinary people can use. The company develops, produces and sells innovative drugs for major diseases such as oncology, cardiovascular and metabolic, autoimmune and ophthalmology. The company has reached more than 30 strategic partnerships with international partners such as Eli Lilly, Sanofi, Incyte, Adimab, LG Chem, and MDanderson Cancer Center. “Beginning with Trust, Achieving Action”, the company adheres to the highest standards of industry standards and hopes to work with industry colleagues to promote the development of the biopharmaceutical industry to meet the broad demand for first-class pharmaceuticals. Product pipeline summary Thanks to the company's multi-functional integrated platform and strategic partnerships, the company has established a strong research pipeline with 36 kinds of high-value products. The company has been approved for marketing of 10 products, namely Cindilizumab Injection (Daberzumab), Bevacizumab Injection (Dayu), Adalimumab Injection (Sulisin), Rituximab Injection (Daboxib), Pemitinib (Dabbotan), Olebatinib (Nellik), Remocizumab Injection (Shiranze), Ceptinib Capsules (Rituil), Iquiolenxil Injection (Fucosil), and Iquiolenxil Injection (Fucosil), and Iquiolenxil Injection (Fucosil) Monoclonal Antibody Injection (Cempira). In addition, there are 3 varieties in the NMPA review, 5 new drug molecules have entered phase III or key clinical research, and 18 new drug types have entered clinical research.